Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose icotinib vs docetaxel/cisplatin after progression on standard-dose icotinib in advanced NSCLC
ChiCTR-IPR-16008240Phase 4Recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Mar 2016
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in non-small cell lung cancer (NSCLC) comparing High-dose icotinib with Docetaxel plus cisplatin chemotherapy (2 arms). Primary endpoint: progression free survival. Started Mar 2016; status: recruiting.
02
Drugs
icotinibdocetaxelcisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-IPR-16008240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-16008240.